{"id":"nct:NCT06932562","kind":"trial","title":"A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant","authors":["European Myeloma Network B.V."],"author_count":1,"year":2025,"published":"2025-04-17","venue":"ClinicalTrials.gov","cited_by":null,"doi":null,"arxiv_id":null,"nct_id":"NCT06932562","source_url":"https://clinicaltrials.gov/study/NCT06932562","archive_url":"https://space-kitty.com/papers/nct:NCT06932562","updated":"2026-03-25","pmid":null,"pmcid":null,"openalex_id":null,"pdf_url":null,"abstract":"This study is researching an experimental drug called linvoseltamab. The study is focused on participants with newly diagnosed multiple myeloma (NDMM) who are ineligible for autologous stem cell transplantation (transplant-ineligible). The main purpose of this study is to compare the effect and safety of linvoseltamab with the effect and safety of the standard treatment.","abstract_license":"ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters","license":"ClinicalTrials.gov terms (attribution, processing date, modifications noted)","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":["Multiple Myeloma"],"details":{"acronym":null,"status":"RECRUITING","phase":"PHASE3","study_type":"INTERVENTIONAL","enrollment":1000,"sponsor":"European Myeloma Network B.V.","conditions":["Multiple Myeloma"],"interventions":["DRUG: Linvoseltamab","DRUG: Daratumumab","DRUG: Lenalidomide","DRUG: Dexamethasone"],"start_date":"2025-12-23","start_date_type":"ACTUAL","primary_completion_date":"2036-12-01","has_results":false,"data_source":"ClinicalTrials.gov","data_processed":"2026-10-29T09:00:05","modifications":"selected fields only; whitespace normalized; brief summary truncated to 2,000 characters"},"provenance":"clinicaltrials","attribution":"Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.","topics":[{"slug":"cancer-immunotherapy","name":"Cancer Immunotherapy","domain_slug":"medicine"}],"cited_in_dossiers":[]}